Data Generation Is Not the Problem. Data Translation Is.

One Idea Worth Acting On.

An MSL spends an hour with a leading oncologist. She fills three pages of notes.

Back at headquarters, the insights system asks for three bullet points.

She submits three bullet points.

The three pages — the clinical questions the oncologist is wrestling with, the patients he is worried about, the competitor data he is skeptical of — disappear into her laptop.

The bottleneck in oncology drug development is not data generation. Every function is generating data. The bottleneck is what happens to it next.

What's Actually Happening

Organizations invest millions in CRM systems, field medical teams, real-world evidence platforms, and digital tools. The assumption is that more data produces better decisions.

It does not. Not if the data never crosses a functional boundary.

The MSL insight that should reach Clinical Development never gets there because the routing system was built for Medical Affairs. The real-world evidence that should inform the market access dossier sits in a HEOR database that Commercial cannot query. The safety signal that appears in patient support call logs never reaches pharmacovigilance because nobody mapped that pathway.

As Christi Shaw, former CEO of Kite and contributor to Voices of Oncology, observed — organizations end up with 120-page s lide decks filled with data points and completely lacking in actionable insight. Data rich. Decision poor.

Why This Matters

Oncology moves faster than any other therapeutic area. By the time siloed information is manually aggregated, interpreted, and circulated to leadership, the strategic window has often already closed.

The MSL who heard the oncologist's concern about a competitor's safety profile three months ago submitted her notes. The notes were summarized. The summary was reviewed. By the time the insight reached a strategy team, the competitor had already addressed the issue at a major congress and the narrative had shifted.

Three months. One compression step at every handoff. Zero decisions changed.

The cost is not just strategic. It is patient-level. Field Medical teams routinely capture feedback about dosing schedules that burden patients and clinics — feedback that, if it reached Clinical Development or CMC early enough, could produce a more convenient formulation or a modified administration route. That feedback sits in unstructured meeting notes and never arrives.

Where It Breaks in the Real World

An MSL hears an oncologist raise a concern about a competitor's safety profile. She submits her notes. The notes are summarized. The summary is reviewed. By the time the insight reaches the strategy team, the competitor has already addressed the issue at a major congress. The narrative has shifted. Three months. One compression step at every handoff. Zero decisions changed. The compression happens at every handoff. The MSL summarizes her notes into the insights system. The insights system produces a report. The report gets presented in a slide deck. The slide deck gets reviewed in a governance meeting where someone asks for a one-page summary.

By the time the original observation reaches a decision-maker, it has been through four layers of interpretation by people who were not in the room when the oncologist said it.

Sarah Clark and Tam Nguyen, OVN's Digital and Technology contributors, describe this as the core data challenge in oncology: it is not that the data does not exist. It is that nobody can find it, query it across systems, or connect it to the decision that needs it.

What Needs to Change

The fix is not another technology platform. Fragmented data plus AI produces faster fragmentation.

The fix is two things together: a cross-functional routing architecture that gets the right insight to the right function without three compression steps, and the organizational will to treat field intelligence as a strategic asset rather than a reporting obligation.

Robin Winter-Sperry, OVN's Field Medical contributor, is precise about what that requires: the MSL's full observation — not the three-bullet summary — needs a pathway to the team whose strategy it should inform. Building that pathway is a governance decision, not a technology decision.

The Bottom Line

The true competitive advantage in oncology does not belong to the organization that generates the most data. It belongs to the organization that can get the right insight to the right decision-maker before the window closes.

Data without translation is just overhead.

Add Your Voice — Where are you seeing this? What's working — and what's not?